Home » Clinical Trials » Beta thalassemia » NCT06024876
NCT06024876

A Clinical Study Evaluating the Safety and Efficacy of Ex-vivo tBE Edited Autologous Hematopoietic Stem Progenitor Cells (CS-101) in Treating Subjects With β-thalassemia

Study Summary

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating β-thalassemia.

Want to learn more about this trial?

Request More Info

Interventions

CS-101BIOLOGICAL
Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique

Study Locations

FacilityCityStateCountry
The First Affiliated Hospital of Guangxi Medical UniversityNanningChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026